Clarify the Role of Opzelura for Eczema

December 2021

Opzelura (ruxolitinib) 1.5% cream will be the first topical Janus kinase (JAK) inhibitor approved for mild to moderate eczema.

It suppresses cytokines to improve itching and inflammation.

Opzelura is thought to be safer than oral JAK inhibitors (Xeljanz, etc)...since it seems to have less than 10% systemic absorption.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote